Vertex will have uptick on June 13 with Lisbon presentation
Thursday June 13 vertex presents data showing second generation correctors with 770/809 fix 50% of cftr function which is equivalent to kalydeco for 551 and enough to reach both heterozygotes and homozygotes. Presentation is first thing in am Spain time and vertex will release data right after presentation so if looking to get in get more do so on by June 12. I anticipate a new 52 week high.
Apparently this work involving second generation correctors showed interesting results in vitro (listen to the webcast done today). If the drugs had been cancer drugs, success in in vitro studies would not move the share price. However, this in vitro efficacy of the drug combination is coming out of Fred van Goor's group. This makes a huge difference. Fred is 3 and 0 in his batting average; all three in vitro successes were translated into clinical successes so far: Kalydeco, VX-809, and VX-661. I agree with Verity that we may see a new high if the CFTR activity increases by more than 50%.
Exactly what I said to dh husband tonight after listening to conference. Also FYI a seeking alpha has transcript up. But what I said was this in vitro data is coming from same folks and lab that got kalydeco, 809, and 661 and he notes that in conference saying that in vitro has translated well into clinical trials. These second generation drugs will be our sons kalydeco.